Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
Oct 15, 2026
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential
MIAMI - Oct. 15, 2026 - PRLog -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP is approaching a pivotal period in its development, with a new FDA update putting its preservative-free ketamine program firmly in focus. On October 15, 2026, the company announced that the U.S. Food and Drug Administration had issued a Discipline Review Letter requesting minor changes to the product's submitted labeling. The FDA also requested sample labeling incorporating the proposed proprietary product name, which remains under review, ahead of the application's November 10, 2026, goal date. Importantly, NRx reported that all requested labeling changes were classified as minor, while final manufacturing process validation runs are underway to support potential commercialization. The announcement provides investors with a defined upcoming regulatory milestone and adds to a broader corporate story encompassing pharmaceutical development, advanced brain stimulation technology, and government-funded clinical research. <Cite refs={["turn117971news13","turn117971search7"]}/>
FDA Update Places November 10 in the Spotlight
NRx's latest announcement marks another important step in its efforts to bring preservative-free intravenous ketamine to the U.S. market through an Abbreviated New Drug Application (ANDA). Ketamine is an established medicine used in clinical settings, and NRx has emphasized the potential value of a preservative-free preparation amid concerns about hospital supply reliability.
The FDA's October 15 letter requests minor labeling revisions and sample labels featuring the proposed product name. This follows the agency's September 15 decision to reclassify an earlier application amendment related to the drug vial from a major amendment to a minor amendment, setting the November 10 GDUFA goal date.
For investors, several developments stand out:
The distinction between progress and approval remains essential. The latest communication does not constitute FDA approval, and the agency's final decision remains pending. Nevertheless, the combination of a defined review date, remaining labeling work, and manufacturing preparation provides a concrete set of milestones for investors to follow. <Cite refs={["turn117971news13","turn117971search7"]}/>
An $11.18 Million DARPA Contract Adds a Major Research Catalyst
NRx's development strategy extends well beyond its immediate ketamine opportunity. On September 30, 2026, its subsidiary NRx Defense Systems announced an approximately $11.18 million prime contract from the Defense Advanced Research Projects Agency (DARPA) to evaluate SPARC-TMS, a clinical research program combining robotic, neuronavigated transcranial magnetic stimulation (TMS) with NRX-101, NRx's investigational oral drug candidate.
The trial is designed to evaluate whether a single-day treatment protocol can help patients with treatment-resistant depression. It brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.
The contract has an 18-month performance period. Approximately $6.7 million was initially obligated, with additional funding dependent on appropriations and the exercise of contract options. Payments are tied to program milestones.
This arrangement offers an important opportunity to advance research while supporting a potentially differentiated treatment approach. If the trial produces encouraging results, it could help establish a foundation for further development of NRX-101 alongside TMS. The clinical results, however, will determine whether the approach can support subsequent regulatory applications.
HOPE Therapeutics Connects Research With Advanced Treatment Technology
NRx's subsidiary HOPE Therapeutics is another important part of the company's strategy. On September 11, NRx announced that HOPE was preparing to deploy Zeta Surgical's FDA-cleared robotic TMS navigation system at its Florida clinics.
The technology is designed to help clinicians position TMS equipment using advanced navigation software. Its potential role in delivering consistent treatment positioning complements the company's interest in combining pharmaceutical candidates with technology-enabled psychiatric care.
This creates a connection between NRx's research pipeline and an operating clinical network. HOPE's facilities may provide experience with advanced treatment delivery and a platform for participating in clinical programs, subject to the applicable study requirements.
Together, the robotic TMS initiative and SPARC-TMS contract give investors another area to monitor as NRx works to develop differentiated approaches for difficult-to-treat depression. <Cite refs={["turn117971search9","turn117971search10"]}/>
NRX-100 and NRX-101 Anchor the Pharmaceutical Pipeline
NRx's two principal drug-development programs address different opportunities.
NRX-100 is the company's preservative-free intravenous ketamine product. In addition to its ANDA, NRx has initiated a separate New Drug Application pathway for potential use in treating suicidal ideation in patients with depression, including bipolar depression. The company has reported FDA Fast Track Designation for this development program.
NRX-101 is an investigational oral combination of D-cycloserine and lurasidone. NRx has pursued its development for serious depression-related conditions, including suicidal bipolar depression, and has reported FDA Breakthrough Therapy Designation for that indication.
These programs offer different potential catalysts and follow distinct regulatory pathways. The near-term focus is the preservative-free ketamine ANDA, while the broader pipeline provides additional opportunities for clinical and regulatory progress.
The SPARC-TMS program is particularly notable because it could explore NRX-101 in combination with robotic brain stimulation for treatment-resistant depression, potentially opening a separate avenue for future development if supported by clinical evidence. <Cite refs={["turn117971news13","turn117971search9"]}/>
Manufacturing Preparation and Financial Resources
NRx has previously reported commercial-scale manufacturing preparations for preservative-free ketamine, including plans to build launch inventory. In its August 17, 2026, second-quarter update, the company described plans for approximately five million doses of launch inventory and additional production following a potential launch.
The company also reported completing an underwritten public offering that generated approximately $22.3 million in gross proceeds. On June 30, 2026, NRx reported approximately $26.7 million in cash and cash equivalents and stated that its resources were expected to support at least one year of operations.
These earlier disclosures provide useful context as the company approaches its next regulatory milestone. Manufacturing validation, cash utilization, additional financing needs, and commercial execution will all be important considerations if approval is obtained. The reported financial position reflects the company's position at the end of the second quarter, rather than a guarantee of its current cash balance or future funding requirements. <Cite refs={["turn117971search10"]}/>
Key NRXP Developments to Watch
The Bottom Line: A Significant Period for NRx Pharmaceuticals
NRx Pharmaceuticals is advancing several interconnected opportunities in neuroscience and mental health, with the preservative-free ketamine review serving as its most immediate regulatory catalyst.
Today's FDA announcement provides a clearer view of the remaining labeling work ahead of the November 10 goal date. At the same time, the DARPA-funded SPARC-TMS program, HOPE Therapeutics' technology initiatives, and the broader NRX-100 and NRX-101 pipeline give investors additional developments to follow.
For more information on $NRXP visit: https://www.nrxpharma.com and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: [email protected]
Phone: (917) 653-5122
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP) | More news from this source
Press release distribution by PRLog
MIAMI - Oct. 15, 2026 - PRLog -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP is approaching a pivotal period in its development, with a new FDA update putting its preservative-free ketamine program firmly in focus. On October 15, 2026, the company announced that the U.S. Food and Drug Administration had issued a Discipline Review Letter requesting minor changes to the product's submitted labeling. The FDA also requested sample labeling incorporating the proposed proprietary product name, which remains under review, ahead of the application's November 10, 2026, goal date. Importantly, NRx reported that all requested labeling changes were classified as minor, while final manufacturing process validation runs are underway to support potential commercialization. The announcement provides investors with a defined upcoming regulatory milestone and adds to a broader corporate story encompassing pharmaceutical development, advanced brain stimulation technology, and government-funded clinical research. <Cite refs={["turn117971news13","turn117971search7"]}/>
FDA Update Places November 10 in the Spotlight
NRx's latest announcement marks another important step in its efforts to bring preservative-free intravenous ketamine to the U.S. market through an Abbreviated New Drug Application (ANDA). Ketamine is an established medicine used in clinical settings, and NRx has emphasized the potential value of a preservative-free preparation amid concerns about hospital supply reliability.
The FDA's October 15 letter requests minor labeling revisions and sample labels featuring the proposed product name. This follows the agency's September 15 decision to reclassify an earlier application amendment related to the drug vial from a major amendment to a minor amendment, setting the November 10 GDUFA goal date.
For investors, several developments stand out:
- Minor labeling requests: The company reports that all changes requested in the latest letter were classified as minor.
- November 10 goal date: This remains the announced FDA review milestone for the ANDA.
- Manufacturing readiness: NRx says final manufacturing process validation runs are underway.
- Product-name review: The proposed proprietary name remains under FDA review.
The distinction between progress and approval remains essential. The latest communication does not constitute FDA approval, and the agency's final decision remains pending. Nevertheless, the combination of a defined review date, remaining labeling work, and manufacturing preparation provides a concrete set of milestones for investors to follow. <Cite refs={["turn117971news13","turn117971search7"]}/>
An $11.18 Million DARPA Contract Adds a Major Research Catalyst
NRx's development strategy extends well beyond its immediate ketamine opportunity. On September 30, 2026, its subsidiary NRx Defense Systems announced an approximately $11.18 million prime contract from the Defense Advanced Research Projects Agency (DARPA) to evaluate SPARC-TMS, a clinical research program combining robotic, neuronavigated transcranial magnetic stimulation (TMS) with NRX-101, NRx's investigational oral drug candidate.
The trial is designed to evaluate whether a single-day treatment protocol can help patients with treatment-resistant depression. It brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.
The contract has an 18-month performance period. Approximately $6.7 million was initially obligated, with additional funding dependent on appropriations and the exercise of contract options. Payments are tied to program milestones.
This arrangement offers an important opportunity to advance research while supporting a potentially differentiated treatment approach. If the trial produces encouraging results, it could help establish a foundation for further development of NRX-101 alongside TMS. The clinical results, however, will determine whether the approach can support subsequent regulatory applications.
HOPE Therapeutics Connects Research With Advanced Treatment Technology
NRx's subsidiary HOPE Therapeutics is another important part of the company's strategy. On September 11, NRx announced that HOPE was preparing to deploy Zeta Surgical's FDA-cleared robotic TMS navigation system at its Florida clinics.
The technology is designed to help clinicians position TMS equipment using advanced navigation software. Its potential role in delivering consistent treatment positioning complements the company's interest in combining pharmaceutical candidates with technology-enabled psychiatric care.
This creates a connection between NRx's research pipeline and an operating clinical network. HOPE's facilities may provide experience with advanced treatment delivery and a platform for participating in clinical programs, subject to the applicable study requirements.
Together, the robotic TMS initiative and SPARC-TMS contract give investors another area to monitor as NRx works to develop differentiated approaches for difficult-to-treat depression. <Cite refs={["turn117971search9","turn117971search10"]}/>
NRX-100 and NRX-101 Anchor the Pharmaceutical Pipeline
NRx's two principal drug-development programs address different opportunities.
NRX-100 is the company's preservative-free intravenous ketamine product. In addition to its ANDA, NRx has initiated a separate New Drug Application pathway for potential use in treating suicidal ideation in patients with depression, including bipolar depression. The company has reported FDA Fast Track Designation for this development program.
NRX-101 is an investigational oral combination of D-cycloserine and lurasidone. NRx has pursued its development for serious depression-related conditions, including suicidal bipolar depression, and has reported FDA Breakthrough Therapy Designation for that indication.
These programs offer different potential catalysts and follow distinct regulatory pathways. The near-term focus is the preservative-free ketamine ANDA, while the broader pipeline provides additional opportunities for clinical and regulatory progress.
The SPARC-TMS program is particularly notable because it could explore NRX-101 in combination with robotic brain stimulation for treatment-resistant depression, potentially opening a separate avenue for future development if supported by clinical evidence. <Cite refs={["turn117971news13","turn117971search9"]}/>
Manufacturing Preparation and Financial Resources
NRx has previously reported commercial-scale manufacturing preparations for preservative-free ketamine, including plans to build launch inventory. In its August 17, 2026, second-quarter update, the company described plans for approximately five million doses of launch inventory and additional production following a potential launch.
The company also reported completing an underwritten public offering that generated approximately $22.3 million in gross proceeds. On June 30, 2026, NRx reported approximately $26.7 million in cash and cash equivalents and stated that its resources were expected to support at least one year of operations.
These earlier disclosures provide useful context as the company approaches its next regulatory milestone. Manufacturing validation, cash utilization, additional financing needs, and commercial execution will all be important considerations if approval is obtained. The reported financial position reflects the company's position at the end of the second quarter, rather than a guarantee of its current cash balance or future funding requirements. <Cite refs={["turn117971search10"]}/>
Key NRXP Developments to Watch
- October 15, 2026: FDA requests minor labeling changes for preservative-free ketamine.
- November 10, 2026: Announced GDUFA goal date for the ketamine ANDA.
- Manufacturing: Final process validation runs are underway, according to the company.
- DARPA contract: Approximately $11.18 million awarded for the SPARC-TMS research program.
- HOPE Therapeutics: Continued development of robotic TMS capabilities.
- NRX-101: Ongoing development of an investigational treatment for serious depression-related conditions.
The Bottom Line: A Significant Period for NRx Pharmaceuticals
NRx Pharmaceuticals is advancing several interconnected opportunities in neuroscience and mental health, with the preservative-free ketamine review serving as its most immediate regulatory catalyst.
Today's FDA announcement provides a clearer view of the remaining labeling work ahead of the November 10 goal date. At the same time, the DARPA-funded SPARC-TMS program, HOPE Therapeutics' technology initiatives, and the broader NRX-100 and NRX-101 pipeline give investors additional developments to follow.
For more information on $NRXP visit: https://www.nrxpharma.com and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: [email protected]
Phone: (917) 653-5122
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP) | More news from this source
Press release distribution by PRLog
More News
Oct 15, 2026
Tesla Debuts 2026 Roadster, an EV Sports Car at Least $200,000
Elon Musk’s company and other automakers, like Jaguar and Bentley, are trying to sell very expensive electric cars to people who usually prefer gasoline-fueled luxury and performance.
Oct 15, 2026
What Allegations of Spying at OpenAI Mean for the A.I. Industry
The arrest of an OpenAI employee accused of planting a bug in an office of the artificial intelligence giant flags another concern for the industry.
Oct 15, 2026
AI giant Anthropic woos potential investors ahead of stock market debut
It comes as some investors have become concerned about the amount of money being spent on AI infrastructure.
Oct 15, 2026
Families of Sailors Killed in Gulf Struggle for Compensation and Closure
Attacks near the Strait of Hormuz have claimed the lives of at least 25 seafarers. Their survivors are reeling.
Oct 15, 2026
Chinese Carmakers, Once a Sideshow, Take Center Stage at Paris Motor Show
At this week’s Paris Motor Show, there are no signs the influx of low-cost Chinese vehicles will slow despite European Union efforts.
Oct 15, 2026
Thousands of NI workers to get pay bump as Real Living Wage rises
About 6,000 workers in NI are paid the Real Living Wage - which is voluntarily paid to reflect the cost of living.
Oct 15, 2026
Graphics: China advances two-way opening-up of its financial markets
Graphics: China advances two-way opening-up of its financial markets
Oct 15, 2026
Bank of America Fined $1.2 Billion for Lax Money-Laundering Oversight
Federal regulators said the bank had waved through suspicious transactions without proper care.
Oct 15, 2026
Musk Blames Tycoon for Stalling Satellite Internet Access in India
As Starlink seeks permission to operate in India, a recent protest in New Delhi showed how quickly authorities can cut off mobile internet access.
Oct 14, 2026
How backlash against data centres could shape the US midterm elections
Democrats and Republicans alike are coming out against data centre development, amid growing backlash across the US.
Oct 14, 2026
As Christmas rush looms, how do China-made toys find their way to the US?
With the festive season on the horizon, we trace toys from factories in China to US shelves.
Oct 14, 2026
How much is the minimum wage?
What are the National Minimum Wage and the National Living Wage, and how much are they worth?
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.